Search
Eniluracil
go.drugbank.com/drugs/DB03516InvestigationalEniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’ … Eniluracil could improve 5-FU by increasing its effectiveness, reducing its side effects and/or making it orally available.
Lesopitron
go.drugbank.com/drugs/DB04970ExperimentalLesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.
Tofersen
go.drugbank.com/drugs/DB14782ApprovedInvestigational[L46133] In June of 2024, it was additionally approved by the EMA for the same indication. … [A259028,A259033] Tofersen was granted accelerated approval from the FDA on April 25, 2023, as the first treatment for adults with ALS caused by SOD1 mutation.
Lovotibeglogene autotemcel
go.drugbank.com/drugs/DB18680ApprovedInvestigational[A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who … exagamglogene autotemcel] (Casgevy), another gene therapy, with the two treatments comprising the first cell-based gene therapies for the treatment of SCD in patients 12 years and older to be approved by
Picoplatin
go.drugbank.com/drugs/DB04874InvestigationalIt causes apoptosis (cell death) by binding to DNA and interfering with DNA replication and transcription.
AZD 3355
go.drugbank.com/drugs/DB05404InvestigationalIt is developed by AstraZeneca and is currently in phase I/II trials.
Povidone
go.drugbank.com/drugs/DB11061ApprovedInvestigationalWithdrawnPovidone, also known as polyvinylpyrrolidone (PVP) or polyvidone, is a synthetic water-soluble polymer made from the monomer N-vinylpyrrolidone used as a binder in many pharmaceutical tablets and lubricant in eye drops. It is also used i...
Mixtures: SK Advanced Relief Eye DropsBismuth subcitrate potassium
go.drugbank.com/drugs/DB09275ApprovedInvestigationalA bismuth compound used for peptic ulcer and gastro-oesophageal reflux disease (GORD).
Opicapone
go.drugbank.com/drugs/DB11632ApprovedInvestigationalOpicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules.
Fezolinetant
go.drugbank.com/drugs/DB15669ApprovedInvestigational[A259542] Fezolinetant was approved by the FDA in May 2023 under the brand name Veozah.[L46422] It was subsequently approved by the EMA in December 2023 for the same indication.[L50086] … [A259591,A259542] By antagonizing NK3 receptors, neuronal signalling can be dampened to reduce VMS.